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Abstract
IMPORTANCE Severe early onset fetal growth restriction caused by placental dysfunction leads to
high rates of perinatal mortality and neonatal morbidity. The phosphodiesterase 5 inhibitor,
sildenafil, inhibits cyclic guanosine monophosphate hydrolysis, thereby activating the effects of nitric
oxide, and might improve uteroplacental function and subsequent perinatal outcomes.
OBJECTIVE To determine whether sildenafil reduces perinatal mortality or major morbidity.
DESIGN, SETTING, AND PARTICIPANTS This placebo-controlled randomized clinical trial was
conducted at 10 tertiary referral centers and 1 general hospital in the Netherlands from January 20,
2015, to July 16, 2018. Participants included pregnant women between 20 and 30 weeks of gestation
with severe fetal growth restriction, defined as fetal abdominal circumference below the third
percentile or estimated fetal weight below the fifth percentile combined with Dopplers
measurements outside reference ranges or a maternal hypertensive disorder. The trial was stopped
early owing to safety concerns on July 19, 2018, whereas benefit on the primary outcome was
unlikely. Data were analyzed from January 20, 2015, to January 18, 2019. The prespecified primary
analysis was an intention-to-treat analysis including all randomized participants.
INTERVENTIONS Participants were randomized to sildenafil, 25 mg, 3 times a day vs placebo.
MAIN OUTCOMES AND MEASURES The primary outcome was a composite of perinatal mortality
or major neonatal morbidity until hospital discharge.
RESULTS Out of 360 planned participants, a total of 216 pregnant women were included, with 108
women randomized to sildenafil (median gestational age at randomization, 24 weeks 5 days
[interquartile range, 23 weeks 3 days to 25 weeks 5 days]; mean [SD] estimated fetal weight, 458
[160] g) and 108 women randomized to placebo (median gestational age, 25 weeks 0 days
[interquartile range, 22 weeks 5 days to 26 weeks 3 days]; mean [SD] estimated fetal weight, 464
[186] g). In July 2018, the trial was halted owing to concerns that sildenafil may cause neonatal
pulmonary hypertension, whereas benefit on the primary outcome was unlikely. The primary
outcome, perinatal mortality or major neonatal morbidity, occurred in the offspring of 65 participants
(60.2%) allocated to sildenafil vs 58 participants (54.2%) allocated to placebo (relative risk, 1.11; 95%
CI, 0.88-1.40; P = .38). Pulmonary hypertension, a predefined outcome important for monitoring
safety, occurred in 16 neonates (18.8%) in the sildenafil group vs 4 neonates (5.1%) in the placebo
group (relative risk, 3.67; 95% CI, 1.28-10.51; P = .008).
(continued)
Key Points
Question Does sildenafil reduce the risk
of perinatal mortality or morbidity in
children of pregnant women with severe
early onset fetal growth restriction?
Findings In this randomized clinical trial
including 216 pregnant women,
perinatal mortality or major morbidity
was not statistically different and
occurred in the offspring of 60.2% of
participants allocated to sildenafil vs
54.2% of those allocated to placebo.
Pulmonary hypertension occurred in
18.8% of neonates in the sildenafil group
compared with 5.1% of neonates in the
placebo group, which was statistically
significantly different.
Meaning These findings suggest that
treatment of severe early onset fetal
growth restriction by maternal sildenafil
did not reduce the risk of perinatal
mortality or major neonatal morbidity,
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Abstract (continued)
CONCLUSIONS AND RELEVANCE These findings suggest that antenatal maternal sildenafil
administration for severe early onset fetal growth restriction did not reduce the risk of perinatal
mortality or major neonatal morbidity. The results suggest that sildenafil may increase the risk of
neonatal pulmonary hypertension.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02277132
JAMA Network Open. 2020;3(6):e205323. doi:10.1001/jamanetworkopen.2020.5323
Introduction
Severe early onset fetal growth restriction is a rare condition, complicating approximately 0.4% of all
pregnancies.1,2 It is associated with a high risk of fetal death, iatrogenic preterm birth, long-lasting
stay at the neonatal intensive care unit, neonatal mortality, and long-term morbidity.3,4 Severe early-
onset fetal growth restriction is also strongly associated with neurodevelopmental impairment later
in childhood.5,6 To our knowledge, no effective treatment to promote fetal growth has been
identified, and management consists of intensive monitoring to determine the best moment to
deliver the fetus, balancing the consequences of prematurity vs undernutrition and hypoxia.7
Recently, phosphodiesterase type 5 inhibitors, most often sildenafil, have been investigated as
potential treatment for fetal growth restriction.8-16 The Sildenafil Therapy in Dismal Prognosis Early
Onset Fetal Growth Restriction (STRIDER) consortium designed and conducted in synchrony 4
randomized clinical trials to study sildenafil’s hypothesized improvement of placental circulation
through its effects on the uteroplacental circulation.8-16 In the Dutch STRIDER trial, the hypothesis
that sildenafil reduces the chance of perinatal mortality and morbidity was tested using a composite
outcome of perinatal mortality and major neonatal morbidity.
Methods
We conducted this placebo-controlled randomized clinical trial in 10 tertiary care centers and 1
general hospital in the Netherlands. Ethical approval was granted by Amsterdam UMC. All
participating women provided written informed consent. The protocol was registered on September
29, 2014 (Trial Protocol in Supplement 1), before the first participant was randomized. This study is
reported following the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.
Study Design
An independent data safety monitoring board (DSMB) monitored the safety of the participants after
data were available for each 50 participants, as well as the efficacy after the outcomes were known
for half of the participants.17 The DSMB charter included the provision to recommend stopping the
trial in case the safety of current or future participants was considered to be compromised.
Furthermore, a stopping rule was included, indicating that the trial would be stopped if a significant
difference between the 2 treatment groups was observed at interim analysis (according to the
O’Brien-Fleming spending function, P < .005).
Participants
Pregnant women were eligible if they were between 20 weeks 0 days and 27 weeks 6 days of
gestation and if the fetal abdominal circumference was below the 3rd percentile or the estimated
fetal weight (EFW) below the 5th percentile, combined with either unilateral or bilateral notching of
the uterine artery, Pulsatility Index (PI) of the umbilical artery above the 95th percentile, PI of the
middle cerebral artery below the 5th percentile, or a maternal hypertensive disorder. Participants
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with gestation between 28 weeks 0 days and 29 weeks 6 days were eligible if the EFW was less than
700 g, combined with the aforementioned Doppler anomalies or a maternal hypertensive disorder,
to select the patients with unfavorable prognosis. Gestational age estimation was based on a first
trimester ultrasound. Exclusion criteria were anticipated imminent termination of pregnancy for
maternal or fetal indications, multifetal pregnancy, identified congenital anomalies (affecting
outcomes), identified congenital infection, maternal age younger than 18 years, cocaine use, current
use of sildenafil, current use of cytochrome P450 3A5 isozyme inhibitors, and recent myocardial
infarction or stroke.
Maternal race/ethnicity was collected because maternal race/ethnicity is associated with
placental dysfunction and pregnancy outcomes.18,19 Whether the maternal race/ethnicity was
European descent, African descent, or Asian descent was indicated by the investigator. In case of
doubt, the patient was asked to report her race/ethnicity.
In participating centers, samples of maternal blood were collected at randomization by
venipuncture and stored at −80 °C for batch testing of placental growth factor (PGF) level.
Measurement of PGF level was performed on the Kryptor immunoassay (Thermo Fisher Scientific)
and compared with the fifth percentile of a reference population (ie, 106.54 pg/mL).20
Randomization and Masking
The web-based randomization had a 1:1 ratio, random block sizes of 2 to 6, and was stratified per
participating center. Participants, clinicians, investigators, and outcome assessors were blinded for
the treatment allocation.
Procedures
Trial medication was manufactured specifically for this trial by Tiofarma, and tablets contained either
sildenafil 25 mg or placebo and were taken orally 3 times daily. Active and placebo medications were
matching in color, size, weight, and taste. The dosage regimen was based on previous studies by the
collaborators on this project.12,15
Participants used the trial medication until fetal death, 32 weeks of gestation, or birth.
Adherence was participant-reported at each antenatal outpatient clinic visit, Additionally, at the end
of the exposure period, medication bottles were collected, and the remaining number of tablets was
counted. Participants kept a record of adverse effects. Trial medication was ended at the discretion of
the patient. The fetal monitoring (ultrasonography and cardiotocography) and interventions other
than the trial medication were at the discretion of the attending gynecologist and in line with Dutch
national guidelines and local protocols, depending on the gestational age and EFW. In most
participating centers, active management was installed after extensive counseling of parents by a
gynecologist and neonatologist and at a minimum gestational age of 26 weeks 0 days combined with
an EFW of 500 g. Data were collected from the patient’s electronic health record and entered into a
secure electronic database (REDCAP).
Outcomes
The primary outcome was a composite of either perinatal mortality or major neonatal morbidity
before the neonate was discharged from the hospital. Major neonatal morbidity was defined as
intraventricular hemorrhage grade 3 or more,21-23 periventricular leukomalacia grade 2 or more,24,25
moderate or severe bronchopulmonary dysplasia,26-30 necrotizing enterocolitis Bell stage 2 or
more,31,32 or retinopathy of prematurity requiring laser therapy.33,34 We defined the neonatal period
as the time until hospital discharge. Mortality after hospital discharge was considered not to be the
mortality of interest in the primary outcome, since the chance of this mortality being associated with
the intervention was considered small.
The secondary outcomes were (1) the proportion of mothers experiencing either pre-eclampsia
or hemolysis, elevated liver enzymes, and low platelets syndrome35; (2) PI of umbilical artery. the
first PI measured at the ultrasound performed more than 24 hours after start trial medication; (3)
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birth weight, with birth weight of live born neonates and birth weight of stillborn fetuses described
separately; (4) gestational age at birth or fetal death; and (5) the proportion of neonates with
neurodevelopmental impairment at age 2 years, assessed on the 2-year Bayley Scales of Infant
Development, Third Edition (BSID-III)36 and its cognitive and motor subscales. The latter secondary
outcome is not reported here because the 2-year follow-up is not yet complete. When possible, we
reported outcomes according to the core outcome set for fetal growth restriction that was
developed after the start of the trial.37
Statistical Analysis
We aimed to find a decrease in the incidence of the primary outcome from 71%15 in the control group
to 56% in the experimental group, which is equal to a relative risk reduction of 21%. Allowing for 10%
loss to follow-up and interim analysis for efficacy according to the O’Brien-Fleming spending function
(P < .005), and with an accepted type I error of 5% and type II error of 80%, we needed to randomize
180 women per group.
The statistical analysis plan, published elsewhere and available in Supplement 1),38 provides the
details of the statistical analysis. In short, the prespecified primary analysis was an intention-to-
treat analysis including all randomized participants. Additionally, several prespecified sensitivity
analyses were conducted for the primary outcome: adjusting for gestational age and EFW at
randomization; only including participants who had a fetus or neonate without any congenital
anomaly that could either explain the small fetal size in hindsight or would have a likely effect on the
primary outcome (originally defined as a subgroup analysis, since not all congenital anomalies can
be known antenatally); and a per-protocol analysis for the primary outcome that included only
participants who used at least 1 tablet of trial medication. Relative risks were calculated using
generalized linear models (log link function), and continuous outcomes were analyzed using linear
regression.38
Predefined subgroup analyses were conducted for participants with a serum level of PGF
(categorized as less than the fifth percentile and fifth percentile or higher), gestational age at
randomization (categorized as <25 weeks of gestation and 25 weeks of gestation), and EFW at
randomization (categorized as <300 g, 300 to 599 g, and 600 g).
All statistical analyses were conducted independently by 2 researchers (C.N. and R.G.D.,
supervised by J.C.J.) using R statistical software version 3.5.1 (R Project for Statistical Computing) and
SAS statistical software version 9.4 (SAS Institute). P values were 2-sided, and statistical significance
was set at P < .05. Data were analyzed from January 20, 2015, to January 18, 2019.
Results
Between January 20, 2015 and July 16, 2018, 281 women were eligible, of whom 216 were
randomized (Figure). Among these, 108 women were randomized to sildenafil (median gestational
age at randomization, 24 weeks 5 days [interquartile range, 23 weeks 3 days to 25 weeks 5 days];
mean [SD] estimate fetal weight, 458 [160] g) and 108 women were randomized to placebo (median
gestational age, 25 weeks 0 days [interquartile range, 22 weeks 5 days to 26 weeks 3 days]; mean
[SD] estimate fetal weight 464 [186] g). On July 19, 2018, the DSMB recommended to discontinue
the trial based on the findings at the interim analysis on the data from the first 183 participants
(eAppendix 1 in Supplement 2). The main consideration for the DSMB to recommend stopping was
an increased incidence of neonatal pulmonary hypertension (a predefined outcome important for
monitoring safety), whereas it was considered unlikely that benefit would be shown on the primary
outcome of perinatal mortality or major neonatal morbidity until hospital discharge if the trial were
continued to its completion. Moreover, no positive effects on the primary, secondary, or exploratory
outcomes, as defined in the statistical analysis plan,38 were seen. The results of the recently
published STRIDER UK trial39 as well as the (at that time unpublished) data of the STRIDER New
Zealand/Australia trial40 were included in the DSMB deliberations, as was foreseen in the DSMB
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charter.17 The trial leadership stopped the trial immediately on July 19, 2018, at which point 7
remaining participants using trial medication were advised to stop using the trial medication, and
drug allocation of all participants was unblinded for the participants and the researchers. Owing to
the unforeseen stopping of the trial, we were not able to carry out all analyses as planned (eAppendix
2 in Supplement 2).
Of 216 participants randomized at the time of halting the trial, 1 participant was lost to follow-up
for all outcomes after having moved abroad, and 12 participants did not start trial medication and
were therefore excluded from the per-protocol analysis. The mean (SD) adherence in the
per-protocol group was 91% (23%) of the tablets taken.
Baseline characteristics are shown in Table 1. There were no clinically relevant differences
between the sildenafil and placebo groups in the maternal or fetal baseline characteristics, other than
a slight imbalance in fetal sex (sildenafil: 51 [47.2%] boys; placebo: 59 [54.6%] boys).
No difference was observed in the composite primary outcome of perinatal mortality or major
neonatal morbidity until hospital discharge: 65 participants (60.2%) in the sildenafil-group and 58
participants (54.2%) in the placebo-group experienced perinatal death or major neonatal morbidity
(relative risk [RR], 1.11; 95% CI, 0.88-1.40; P = .38) (Table 2). Bayes factor analysis indicated that the
results on the primary outcome were 3.7-fold more likely compatible with no effect than with the risk
reduction hypothesized in the sample size calculation. No differences were observed in the
subcomponents of the primary outcome. Perinatal mortality was comparable (sildenafil: 44 deaths
[40.7%]; placebo: 40 deaths [37.4%]; RR, 1.09; 95% CI, 0.78-1.52; P = .61). Two more children in the
sildenafil group died after hospital discharge: 1 died 1 day after hospital discharge owing to sepsis
resulting from necrotizing enterocolitis; another died at age 18 months owing to cardiogenic shock
resulting from sepsis. Trial sequential analysis on the data from this trial showed that the boundary
for futility was crossed for the primary outcome (eAppendix 3 in Supplement 2).
The proportion of mothers experiencing either pre-eclampsia or hemolysis, elevated liver
enzymes, and low platelets syndrome was 46 mothers (42.6%) in the sildenafil group vs 48 mothers
(44.9%) in the group allocated to placebo (RR, 0.95; 95% CI, 0.70-1.29) (Table 3). The mean PI of
the maternal uterine artery or the fetal umbilical and middle cerebral artery arteries after treatment
with study medication did not differ between groups (eTable 1 in Supplement 2).
Figure. CONSORT Flow Diagram
281 Assessed for eligibility
65 Excluded
65 Declined to participate
108 Analyzed
5 Excluded from per-protocol analysis; did not start
intervention
0 Excluded from intention-to-treat analysis
107 Analyzed
7 Excluded from per-protocol analysis; did not start
intervention
1 Excluded from intention-to-treat analysis
108 Allocated to sildenafil
103 Received allocated intervention
5 Did not receive allocated intervention
3 Birth before start of intervention
1 Intrauterine death before start of intervention
1 Did not start intervention on participant
request
108 Allocated to placebo
101 Received allocated intervention
7 Did not receive allocated intervention
6 Birth before start of intervention
1 Intrauterine death before start of intervention
0 Lost to follow-up 1 Lost to follow-up (moved out of the country during
pregnancy)
216 Randomized
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No difference in birth weight was observed between the treatment groups. Mean (SD) birth
weight of the neonates who were stillborn was 414 (143) g in the sildenafil group vs 362 (115) g in the
placebo group (P = .15). Mean (SD) gestational age of birth or fetal death was 29 weeks 3 days (4
weeks 0 days) in the sildenafil group vs 29 weeks 3 days (4 weeks 3 days) in the placebo group
(P > .99).
The results of all exploratory outcomes are reported in Table 2 and Table 3. Because the DSMB
based their advice to stop the trial on the increased occurrence of neonatal pulmonary hypertension
in the sildenafil group, we composed an expert adjudication committee of 4 neonatologists (W.O.,
A.F.J.v.H., I.K.M.R., and E.L.) experienced in treating neonates who are preterm and growth
restricted and a pediatric cardiologist (R.M.F.B.) knowledgeable on the subject of neonatal and
pediatric pulmonary hypertension to carefully review this outcome. The committee, blinded for
treatment allocation, reviewed all neonatal records with the purpose of consensus validation of this
diagnosis after discontinuation of the trial. Persistent pulmonary hypertension was defined as either
confirmed by cardiac ultrasonagraphic examination or as a difference in oxygen saturation between
the right upper extremity and either lower extremity (ie, postductal) of more than 10%. There was an
increase of neonates in the sildenafil group who experienced pulmonary hypertension vs the placebo
group (16 of 85 neonates [18.8%] vs 4 of 78 neonates [5.1%]; RR, 3.67; 95% CI, 1.28-10.51; P = .008).
The adjudication committee observed that 2 different forms of pulmonary hypertension had
occurred (eTable 2 in Supplement 2), including persistent pulmonary hypertension in the neonate
Table 1. Baseline Characteristics
Characteristic
No. (%)
Sildenafil (n = 108) Placebo (n = 108)
Age, mean (SD), y 31 (5.1) 31 (5.0)
BMI, mean (SD) 26 (4.7) 26 (5.8)
Race/ethnicity, descent
European 84 (77.8) 86 (79.6)
African 7 (6.5) 11 (10.2)
Asian 2 (1.9) 5 (4.6)
Other 13 (12.0) 6 (5.6)
Maternal smoking 13 (12.0) 10 (9.3)
Gestational age at randomization, median (IQR), wk 24 5/7 (23 3/7 to 25 5/7) 25 0/7 (22 5/7 to 26 3/7)
Ultrasonagraphic examination results, mean (SD)
Estimated fetal weight, g 458 (160) 464 (186)
Fetal abdominal circumference, mm 165 (2) 164 (26)
Sex
Boys 51 (47.2) 59 (54.6)
Girls 57 (52.8) 48 (44.4)
Notching uterine artery (1- or 2-sided) 61 (56.5) 64 (59.3)
PI
Umbilical artery >95th percentile 51 (47.2) 53 (49.1)
Middle cerebral artery <5th percentile 47 (43.5) 43 (39.8)
End-diastolic flow
Positive 73 (67.6) 65 (60.2)
Absent 27 (25.0) 33 (30.6)
Reversed 7 (6.5) 7 (6.5)
Pregnancy hypertension 22 (20.4) 24 (22.2)
Pre-eclampsia 23 (21.3) 26 (24.1)
HELLP syndrome 1 (0.9) 2 (1.9)
Blood pressure, mean (SD), mm Hg
Systolic 132 (22) 132 (20)
Diastolic 83 (15) 83 (15)
PGF <5th percentile of reference value, No./total No. (%)a 56/61 (91.8) 53/59 (89.8)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); HELLP, hemolysis, elevated liver enzymes,
and low platelets; IQR, interquartile range; PI,
Pulsatility Index; PGF, placental growth factor.
a Reference value was 106.54 pg/L; 5th percentile of
reference population.
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and later-onset pulmonary hypertension associated with either sepsis or bronchopulmonary
dysplasia. Neonatal death was attributable to pulmonary hypertension in 4 infants, 2 in each group
(eTable 2 and eTable 3 in Supplement 2). We plan to publish a separate article on the diagnosis of
pulmonary hypertension and the validation process within the trial.
No subgroup differences were detected when assessed by adding interaction terms to the
models, and the sensitivity analyses did not lead to statistically significant results on the primary
outcome (Table 4). However, the RR slightly increased when analyses were adjusted for gestational
age and EFW at inclusion (RR, 1.23; 95% CI, 0.69-2.23; P = .48) and in a post hoc analysis that
explored the potential effect of the imbalance of sex at inclusion (RR, 1.33; 95% CI,
0.77-2.30; P = .31).
We observed 10 maternal and 2 fetal or neonatal serious adverse events in the sildenafil group
vs 8 maternal and 2 fetal or neonatal serious adverse events in the placebo group that could be
directly attributed to the high-risk nature of the study population (eg, hospitalization of the neonate)
(eTable 4 in Supplement 2). Other than pulmonary hypertension, there were no differences in the
Table 2. Fetal or Neonatal Outcomes (Intention-to-Treat Analysis)a
Outcome
No./total No. (%)
RR (95% CI) Mean difference (95% CI) P valueSildenafil Placebo
Primary outcomeb 65/108 (60.2) 58/107 (54.2) 1.11 (0.88 to 1.40) NA .38
Birth weight, mean (SD), g 829 (537) 884 (627) NA −55 (−211 to 101) .49
Stillbirth 23/108 (21.3) 29/107 (27.1) 0.79 (0.49 to 1.27) NA .32
Birth weight, mean (SD), g 414 (143) 362 (115) NA 53 (−17 to 123) .15
Percentilec
<Tenth 10/13 (76.9) 11/11 (100) 0.77 (0.57 to 1.04) NA .08
<Third 8/13 (61.5) 10/11 (90.9) 0.68 (0.42 to 1.08) NA .10
Live birth 85/108 (78.7) 78/107 (72.9) 1.08 (0.93 to 1.26) NA .32
Birth weight, mean (SD), g 942 (549) 1078 (628) NA −136 (−318 to 44) .14
Percentilec
<Tenth 33/73 (45.2) 30/68 (44.1) 1.02 (0.71 to 1.48) NA .90
<Third 20/73 (27.4) 19/68 (27.9) 0.98 (0.57 to 1.67) NA .94
Apgar score 5 min <7 32/108 (37.6) 25/107 (32.1) 1.17 (0.77 to 1.79) NA .46
Cord blood gas pH <7.10 2/48 (4.2) 0/31 (0)
Neonatal death 21/85 (24.7) 11/78 (14.1) 1.75 (0.9 to 3.39) NA .10
Survival
At hospital discharge 64/85 (75.3) 67/78 (85.9) 0.88 (0.75 to 1.02) NA .09
With major morbidity at hospital discharge 21/85 (24.7) 18/78 (23.1) 1.07 (0.62 to 1.85) NA .81
Without major morbidity at hospital discharge 43/85 (50.6) 49/78 (62.8) 0.81 (0.61 to 1.06) NA .12
Postmenstrual age at first discharge home, mean (SD), wk 42 (7.9) 40 (2.3) NA 2.04 (0.04 to 4.03) .047
IVH grade III or IV 3/85 (3.5) 2/78 (2.6) 1.38 (0.24 to 8.02) NA .72
PVL grade II or more 0/85 (0) 0/78 (0) NA >.99
BPD
Moderate or severe 23/85 (27.1) 16/78 (20.5) 1.32 (0.75 to 2.31) NA .33
None 41/85 (48.2) 47/78 (60.3) 0.80 (0.61 to 1.06) NA .13
ROP treated by laser or surgery 8/85 (9.5) 3/78 (3.8) 2.45 (0.67 to 8.9) NA .17
1 or more culture-proven episode of infection or clinical
episode of infection with antibiotic treatment necessary ≥5 d
44/85 (51.8) 35/78 (44.9) 1.15 (0.84 to 1.59) NA .38
NEC grade II or more 7/85 (8.3) 8/78 (10.3) 0.80 (0.31 to 2.11) NA .66
Abdominal circumference, initial growth rate between
randomization and 14 d, mean (SD), mm/wk
7.4 (6.2) 8.8 (7.3) NA −1.4 (−3.43 to 0.69) .19
Abbreviations: BPD, bronchopulmonary dysplasia; EFW, estimated fetal weight; IVH,
intraventricular hemorrhage; NA, not applicable; NEC, necrotizing enterocolitis; PVL,
periventricular leukomalacia; ROP, retinopathy of prematurity; RR, relative risk.
a Intention-to-treat analysis corrected for gestational age and EFW at randomization,
and per-protocol analysis had similar results.
b The primary outcome was perinatal death or major neonatal morbidity before
discharge.
c Birth weight percentiles were only calculated for infants born after 23 weeks
gestational age.
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other serious adverse events. Several adverse effects of the trial medication with different
frequencies were reported by the participants and are presented in eTable 5 in Supplement 2. The
primary causes of neonatal death and the congenital anomalies observed are described in eTable 6
and eTable 7 in Supplement 2.
Discussion
This randomized clinical trial found that sildenafil compared with placebo did not reduce the risk of
perinatal mortality or major neonatal morbidity. This finding is in line with 2 other published STRIDER
trials from the UK39 and from New Zealand and Australia,40 and is confirmed by trial sequential
analysis of this outcome that includes all 3 trials.
Our present finding of an increased incidence of pulmonary hypertension after antenatal
sildenafil administration was not observed in the 2 other STRIDER trials.39,40 This difference may be
explained by definition differences, diagnostic strategies, or thresholds of suspicion. Our finding may
indicate an important safety signal, and causality is a possibility because sildenafil targets the
pulmonary vasculature. We hypothesize that the causal mechanisms might be rebound
vasoconstriction (or lack of dilatation) of the pulmonary arteries to structural changes within the
pulmonary vasculature.
Table 3. Maternal Outcomes (Intention-to-Treat Analysis)a
Outcome
No./total No. (%)
RR (95% CI) Mean difference (95% CI) P valueSildenafil Placebo
Treatment duration, mean (SD), d 24/108 (18) 20/107 (43) NA 3.73 (−5.44 to 12.91) .43
Gestational age at birth, mean (SD), wk 29 3/7 (4 0/7) 29 3/7 (4 3/7) NA −0.01 (−1.12 to 1.11) .99
Preterm birth, wk
<28 46/108 (42.6) 48/107 (44.9) 0.95 (0.70 to 1.29) NA .74
<37 97/108 (89.8) 90/107 (84.1) 1.07 (0.96 to 1.18) NA .22
Pregnancy prolongation after randomization,
mean (SD), d
34 (28) 33 (32) NA 0.64 (−7.4 to 8.67) .88
Mode of delivery .46
Cesarean
NA
On fetal indication 57/108 (52.8) 51/107 (47.7) NA NA
On maternal indication 14/108 (13.0) 14/107 (13.1) NA NA
Induced vaginal birth
On fetal indication 7/108 (6.5) 12/107 (11.2) NA NA
On maternal indication 8/108 (7.4) 3/107 (2.8) NA NA
Spontaneous vaginal birth 9/108 (8.3) 11/107 (10.3) NA NA
Induction of labor after intrauterine death 12/108 (11.1) 16/107 (15.0) NA NA
Pregnancy hypertension 74/108 (68.5) 72/107 (67.3) 1.02 (0.85 to 1.22) NA .85
Pre-eclampsia 42/108 (38.9) 44/107 (41.1) 0.95 (0.68 to 1.31) NA .74
HELLP syndrome 12/108 (11.1) 10/107 (9.3) 1.19 (0.54 to 2.63) NA .67
Maternal use of antihypertensive treatment
antenatal or postnatal, No. used
None 50/108 (46.3) 53/107 (49.5) NA NA .61
1 32/108 (29.6) 34/107 (31.8) NA NA
2 16/108 (14.8) 15/107 (14.0) NA NA
≥3 10/108 (9.3) 5/107 (4.7) NA NA
Maternal magnesium sulphate for hypertension 14/108 (13.0) 15/107 (14.0) 0.92 (0.47 to 1.82) NA .82
Antenatal corticosteroids for fetal lung
maturation before birth
48 h to 14 d (complete course) 52/85 (61.2) 56/78 (71.8) 0.85 (0.68 to 1.06) NA .15
<48 h (incomplete course) 4/85 (4.8) 7/78 (9.0) 0.52 (0.16 to 1.72) NA .29
Abbreviation: NA, not applicable; HELLP, hemolysis, elevated liver enzymes, and low
platelets; RR, relative risk.
a Intention-to-treat analysis corrected for gestational age and estimated fetal weight at
randomization. Per-protocol analysis had similar results.
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The Canadian STRIDER trial (NCT02442492) was terminated based on the results of this STRIDER
trial. The planned individual patient data analysis that combines our data with all other STRIDER trials
will have more power to draw conclusions based on all available data and hopefully to allow meaningful
subgroup analysis to identify if there are specific participant groups that experience harm or benefit from
the intervention.41
Limitations
Our trial has limitations. First, the trial was stopped before the planned sample size was reached
because of an increased incidence of pulmonary hypertension in the sildenafil group, as well as
indications of futility in our primary outcome. Pulmonary hypertension was predefined as an
important safety outcome to monitor, but it was neither defined as a primary or secondary outcome,
and pulmonary hypertension is a nonvalidated surrogate outcome regarding more patient-centered
outcomes. Although each adverse event should be seriously regarded,42 it might be argued that the
pulmonary hypertension result should only be regarded as hypothesis-generating and should be
tested in the planned individual patient data analysis.41 Second, when assessing the primary outcome
of perinatal mortality or major neonatal morbidity, the trial sequential analysis showed that the
boundary for futility was crossed, indicating that we could reject that sildenafil reduces the risk of the
primary outcome by 20%. However, we cannot reject that sildenafil reduces the risk of the primary
outcome by smaller and perhaps clinically important margins, or that sildenafil reduces the risk of any
of the secondary outcomes.
It could be argued that the trial was stopped too soon owing to the lack of robustness on the
findings of harm. However, the advice of the independent DSMB was not only based on potential
harms but also on lack of benefits. In addition to the increase in pulmonary hypertension observed
at the interim analysis, it became evident that it was unlikely that benefit of sildenafil treatment
would be shown on the primary outcome if the trial were continued to its completion. This was also
demonstrated in the trial sequential analysis on the primary outcome that showed that the boundary
for futility was crossed when taking the results of the UK39 and Australian/New Zealand40 STRIDER
trials into account.
Table 4. Prespecified Sensitivity and Subgroup Analyses on the Primary Outcome According to Treatment
Analysis
No./total No. (%)
RR (95% CI) P valueaSildenafil Placebo
Sensitivity
Per protocol 60/103 (58.3) 54/100 (54.0) 1.08 (0.85-1.38) .54
Adjusted for EFW and GA at randomization 65/108 (60.2) 58/107 (54.2) 1.23 (0.69-2.23) .48
Post hoc adjustment for sex 65/108 (60.2) 58/107 (54.2) 1.33 (0.77-2.30) .31
Excluding
Neonates who appeared to have a
congenital anomaly
60/102 (58.8) 54/101 (53.5) 1.10 (0.86-1.40) .44
Participants who were pregnant or for
whom the neonate was admitted at NICU
when trial was stopped (post hoc)
60/97 (61.9) 55/98 (56.1) 1.10 (0.87-1.39) .42
Placental growth factor, percentile of the
reference value
<Fifth 36/56 (64.3) 25/53 (47.2) 1.36 (0.96-1.93)
.99
≥Fifth 4/5 (80.0) 3/6 (50.0) 1.60 (0.64-3.98)
GA at randomization, wk
<25 42/60 (70.0) 36/54 (66.7) 1.05 (0.82-1.35)
.85
≥25 23/48 (47.9) 22/53 (41.5) 1.15 (0.75-1.78)
EFW at randomization, g
<300 15/19 (78.9) 21/26 (80.8) 0.98 (0.73-1.32)
.70300-599 44/67 (65.7) 23/48 (47.9) 1.37 (0.97-1.93)
≥600 3/18 (16.7) 10/26 (38.5) 0.43 (0.14-1.36)
Abbreviations: EFW, estimated fetal weight; GA,
gestational age; NICU, neonatal intensive care unit; RR,
relative risk.
a The P value is from the interaction term for subgroup
analyses and from the treatment effect for the
sensitivity analyses.
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It could also be argued that the STRIDER trials were premature. However, there was extensive
evidence in appropriate animal models of fetal growth restriction and increasing human evidence
suggesting potential for a positive effect on fetal growth.8 The dosage used in this study (ie, 25 mg 3
times daily) was based on a previous trial15 and is slightly higher than the dosage used for the
treatment of pulmonary hypertension in adults. A meta-analysis of animal studies8 suggested that a
higher dosage than the current study used might be necessary to reach adequate serum levels of
sildenafil. Sildenafil is approved to improve exercise ability and delay clinical worsening of pulmonary
arterial hypertension in adult patients (World Health Organization Group I). In 2012, the US Food and
Drug Administration recommended that sildenafil should not be prescribed to children ages 1
through 17 years for pulmonary arterial hypertension.43 However, there were no reported safety
concerns for the use of sildenafil in fetal growth restriction. In contrast, there was an ongoing
inclusion of this drug into clinical practice in this at-risk patient category.44 Adequately powered
randomized clinical trials are necessary to assess the validity of an intervention before it is
implemented. The concerted approach of the STRIDER trials aimed to prevent premature
implementation of sildenafil based a few underpowered trials and sought to thoroughly test the
beneficial claims before implementation.12,14,15
Conclusions
This randomized clinical trial found that antenatal maternal sildenafil administration for severe early
onset fetal growth restriction did not reduce the risk of perinatal death or major neonatal morbidity.
Our results suggest that sildenafil may increase the risk of neonatal pulmonary hypertension.
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